RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Raises Price Target to $110
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Neurocrine Biosciences (NASDAQ:NBIX) and raised the price target from $108 to $110.

August 04, 2023 | 11:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has maintained its 'Sector Perform' rating on Neurocrine Biosciences and raised the price target from $108 to $110.
The news of RBC Capital maintaining its 'Sector Perform' rating on Neurocrine Biosciences and raising the price target is likely to have a positive impact on the company's stock in the short term. Investors often use such ratings and price targets as a guide for making investment decisions. The increase in the price target suggests that the analyst sees potential for the stock's price to rise.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100